专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007048088A2 METHOD OF INHIBITING FLT3 KINASE 审中-公开
标题翻译：抑制FLT3激酶的方法
公开(公告)号：WO2007048088A2
公开(公告)日：2007-04-26
申请号：PCT/US2006/060028
申请日：2006-10-17
申请人： JANSSEN PHARMACEUTICA N.V. , BALLENTINE, Shelley, K. , BAUMANN, Christian, Andrew , CHEN, Jingsheng , ILLIG, Carl, R. , MEEGALLA, Saneth , RUDOLPH, M. Jonathan , TUMAN, Robert, W. , WALL, Mark, J. , WILSON, Kenneth , JOHNSON, Dana, L.
发明人： BALLENTINE, Shelley, K. , BAUMANN, Christian, Andrew , CHEN, Jingsheng , ILLIG, Carl, R. , MEEGALLA, Saneth , RUDOLPH, M. Jonathan , TUMAN, Robert, W. , WALL, Mark, J. , WILSON, Kenneth , JOHNSON, Dana, L.
IPC分类号： A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/5355
CPC分类号： A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/5355 , Y10S514/908
摘要： A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
摘要翻译：减少或抑制细胞或受试者中FLT3的激酶活性的方法，以及使用本发明化合物（I）使用这些化合物在受试者中预防或治疗细胞增殖性疾病和/或与FLT3相关的病症）或其溶剂合物，水合物，互变异构体或其药学上可接受的盐。本发明还涉及治疗诸如癌症和其它细胞增殖性疾病的病症的方法。

2. 发明申请

WO2006135721A1 ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS 审中-公开
标题翻译：烷基胆碱和碱性氨基酸激酶调节剂
公开(公告)号：WO2006135721A1
公开(公告)日：2006-12-21
申请号：PCT/US2006/022414
申请日：2006-06-07
申请人： JANSSEN PHARMACEUTICA N.V. , BAINDUR, Nand , GAUL, Michael David , KREUTTER, Kevin, Douglas , XU, Guozhang , TUMAN, Robert, W. , JOHNSON, Dana, L. , BAUMANN, Christian, Andrew , KIM, Alexander, J.
发明人： BAINDUR, Nand , GAUL, Michael David , KREUTTER, Kevin, Douglas , XU, Guozhang , TUMAN, Robert, W. , JOHNSON, Dana, L. , BAUMANN, Christian, Andrew , KIM, Alexander, J.
IPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/517 , A61P35/00
CPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
摘要： The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c kit and/or TrkB . The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
摘要翻译：本发明涉及式I的烷基喹啉和烷基喹唑啉化合物：其中R 1，R 2，R 3，B，Z，G，Q和X如本文所定义，使用这些化合物作为蛋白质酪氨酸激酶调节剂，特别是FLT3抑制剂， /或c试剂盒和/或TrkB，使用这些化合物降低或抑制细胞或受试者中FLT3和/或c试剂盒和/或TrkB的激酶活性，以及使用这些化合物预防或治疗患有与FLT3和/或c试剂盒和/或TrkB相关的细胞增殖性疾病和/或障碍。本发明进一步涉及包含本发明化合物的药物组合物和治疗诸如癌症和其它细胞增殖性疾病的病症的方法。

3. 发明申请

WO2003097609A1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS 审中-公开
标题翻译：作为PDFG受体抑制剂的N-取代三聚3-氨基吡唑
公开(公告)号：WO2003097609A1
公开(公告)日：2003-11-27
申请号：PCT/US2003/015193
申请日：2003-05-13
申请人： JANSSEN PHARMACEUTICA N.V. , HO, Chih, Yung , BRUNMARK, Bengt, Anders , EMANUEL, Stuart , GALEMMO JR., Robert, A. , JOHNSON, Dana, L. , LUDOVICI, Donald, W. , MAHAROOF, Umar , MEI, Jay, M. , SECHLER, Jan, L. , STROBEL, Eric, D. , TUMAN, Robert, W. , YEN, Hwa, Kwo
发明人： HO, Chih, Yung , BRUNMARK, Bengt, Anders , EMANUEL, Stuart , GALEMMO JR., Robert, A. , JOHNSON, Dana, L. , LUDOVICI, Donald, W. , MAHAROOF, Umar , MEI, Jay, M. , SECHLER, Jan, L. , STROBEL, Eric, D. , TUMAN, Robert, W. , YEN, Hwa, Kwo
IPC分类号： C07D231/54
CPC分类号： C07F9/65038 , C07D231/54 , C07D231/56 , C07D233/64 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/12 , C07D491/04 , C07D495/04
摘要： The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the presentinvention and to methods for treating conditions such as tumors and other cell proliferative disorders.
摘要翻译：本发明涉及可用作血小板衍生生长因子受体（PDGF-R）激酶抑制剂的N-取代三环3-氨基吡唑衍生物，以及制备所述衍生物的方法。本发明进一步涉及包含本发明化合物的药物组合物和用于治疗诸如肿瘤和其它细胞增殖性疾病的病症的方法。

4. 发明申请

WO2006101937A1 ACYLHYDRAZONES AS KINASE MODULATORS 审中-公开
标题翻译： ACYLHYDRAZONES作为激酶调节剂
公开(公告)号：WO2006101937A1
公开(公告)日：2006-09-28
申请号：PCT/US2006/009425
申请日：2006-03-16
申请人： JANSSEN PHARMACEUTICA N.V. , LEONARD, Kristi , LU, Tianbao , TUMAN, Robert W. , JOHNSON, Dana, L. , MARONEY, Anna, C. , SECHLER, Jan, L. , CONNORS, Richard, W. , ALEXANDER, Richard, S. , CUMMINGS, Maxwell, D. , GALEMMO, Robert, W. , MARKOTAN, Thomas, P.
发明人： LEONARD, Kristi , LU, Tianbao , TUMAN, Robert W. , JOHNSON, Dana, L. , MARONEY, Anna, C. , SECHLER, Jan, L. , CONNORS, Richard, W. , ALEXANDER, Richard, S. , CUMMINGS, Maxwell, D. , GALEMMO, Robert, W. , MARKOTAN, Thomas, P.
IPC分类号： A61K31/404 , A61P35/00
CPC分类号： C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12
摘要： Abstract The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
摘要翻译：摘要本发明涉及式I的酰腙化合物：其中R 1，R 2和A如本文所定义，使用这些化合物作为蛋白质酪氨酸激酶调节剂，特别是c-Met的抑制剂，以及这些化合物用于减少或抑制细胞或受试者中c-Met的激酶活性，并调节细胞或受试者中的c-Met表达，以及使用这些化合物在受试者中预防或治疗细胞增殖性疾病和/或与c相关的疾病 -Met。本发明进一步涉及包含本发明化合物的药物组合物和治疗诸如癌症和其它细胞增殖性疾病的病症的方法。

5. 发明申请

WO1997026258A1 ANGIOGENESIS INHIBITING PYRIDAZINAMINES 审中-公开
标题翻译：血管生成抑制吡咯烷胺
公开(公告)号：WO1997026258A1
公开(公告)日：1997-07-24
申请号：PCT/EP1997000201
申请日：1997-01-14
申请人： JANSSEN PHARMACEUTICA N.V. , STOKBROEKX, Raymond, Antoine , VAN DER AA, Marcel, Jozef, Maria , WILLEMS, Marc , MEERPOEL, Lieven , LUYCKX, Marcel, Gerebernus, Maria , TUMAN, Robert, W.
发明人： JANSSEN PHARMACEUTICA N.V.
IPC分类号： C07D417/04
CPC分类号： C07D417/04 , C07D417/14
摘要： This invention concerns compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is CH or N; m is 2 or 3 and n is 1, 2 or 3; wherein 1 or 2 C-atoms of the CH2 groups of the (a) moiety, which may also contain one double bond, may be substituted with C1-6alkyl, amino, aminocarbonyl, mono- or di(C1-6alkyl)amino, C1-6alkyloxycarbonyl, C1-6alkylcarbonylamino, hydroxy or C1-6alkyloxy; and/or 2 C-atoms of said CH2 groups may be bridged with C2-4alkanediyl; R is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-6alkyl)amino, Ar, ArNH-, C3-6cycloalkyl, hydroxymethyl or benzyloxymethyl; R and R are hydrogen, or taken together may form a bivalent radical of the formula -CH=CH-CH=CH-; in case X represents CH then L is a radical L , L or L ; or in case X represents N then L is a radical L or L ; L is Ar-C1-6alkyloxy, Ar-oxy, Ar-thio, Ar-carbonylamino, di-Ar-methyloxy-, N-Ar-piperazinyl, N-Ar-homopiperazinyl, 2-benzimidazolinonyl, Ar-NR -, Ar-Alk-NR -, Ar-NR -Alk-NR - or Het-NR -; L is Ar, Ar-carbonyl, Ar-CH=CH-CH2-, naphtalenyl or Het; L is C1-6alkyl substituted with one or two radicals selected from Ar, Ar-oxy, or Ar-thio, further optionally substituted with cyano or hydroxy; 2,2-dimethyl-1,2,3,4-tetrahydro-naphtalenyl; 2,2-dimethyl-1H-2,3-dihydroindenyl; Ar-piperidinyl or Ar-NR -Alk-; R and R are each independently selected from hydrogen or C1-6alkyl; Alk is C1-6alkanediyl; their preparation, compositions containing them and their use as a medicine.
摘要翻译：本发明涉及式（I）的化合物，N-氧化物形式，其药学上可接受的酸加成盐和立体化学异构形式，其中X是CH或N; m为2或3，n为1,2或3; 其中也可以含有一个双键的（a）部分的CH 2基团的1或2个C原子可以被C 1-6烷基，氨基，氨基羰基，一或二（C 1-6烷基）氨基，C 1 1-6烷氧基羰基，C 1-6烷基羰基氨基，羟基或C 1-6烷氧基; 和/或所述CH 2基团的2个C原子可以与C 2-4烷二基桥接; R 1是氢，C 1-6烷基，C 1-6烷氧基，C 1-6烷硫基，氨基，单或二（C 1-6烷基）氨基，Ar，ArNH-，C 3-6环烷基，羟甲基或苄氧基甲基; R 2和R 3是氢或一起可以形成式-CH = CH-CH = CH-的二价基团; 在X表示CH的情况下，L是基团L 1，L 2或L 3; 或者在X表示N的情况下，L是基团L 2或L 3; L 1是Ar-C 1-6烷氧基，Ar-氧基，Ar-硫基，Ar-羰基氨基，二-Ar-甲氧基 - ，N-Ar-哌嗪基，N-Ar-高哌嗪基，2-苯并咪唑啉酮基，Ar- Ar-Alk-NR 4 - ，Ar-NR 4 -Alk-NR 5 - 或Het-NR 4 - ; L 2是Ar，Ar-羰基，Ar-CH = CH-CH 2 - ，萘基或Het; L 3是被一个或两个选自Ar，Ar-氧基或Ar-硫基的基团取代的C 1-6烷基，进一步任选被氰基或羟基取代; 2,2-二甲基-1,2,3,4-四氢naphtalenyl; 2,2-二甲基-1H-2,3-二氢; Ar-哌啶基或Ar-NR 4 -Alk-; R 4和R 5各自独立地选自氢或C 1-6烷基; Alk是C1-6烷二基; 其制剂，含有它们的组合物及其作为药物的用途。

6. 发明申请

WO2006138155A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR 审中-公开
标题翻译：使用FLT3抑制剂和FARNESYL转移酶抑制剂的FLT3激酶的协同调节
公开(公告)号：WO2006138155A1
公开(公告)日：2006-12-28
申请号：PCT/US2006/022412
申请日：2006-06-07
申请人： JANSSEN PHARMACEUTICA N.V. , BAUMANN, Christian, Andrew , GAUL, Michael David , TUMAN, Robert, W. , JOHNSON, Dana, L.
发明人： BAUMANN, Christian, Andrew , GAUL, Michael David , TUMAN, Robert, W. , JOHNSON, Dana, L.
IPC分类号： A61K31/4427 , A61P35/00 , A61K31/00
CPC分类号： A61K45/06 , A61K31/4427 , A61K31/454 , A61K2300/00
摘要： The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula (I'). Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.
摘要翻译：本发明涉及一种抑制FLT3酪氨酸激酶活性或表达或降低细胞或受试者中FLT3激酶活性或表达的方法，其包括施用法呢基转移酶抑制剂和选自式（I'）化合物的FLT3激酶抑制剂，。本发明包括预防和治疗方法，用于治疗患有（或易于）发展细胞增殖性病症或与FLT3相关的病症的受试者。

7. 发明申请

WO2006135629A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES 审中-公开
标题翻译：使用烷基喹啉和烷基喹喔啉的FLT3激酶的协同调节
公开(公告)号：WO2006135629A1
公开(公告)日：2006-12-21
申请号：PCT/US2006/022100
申请日：2006-06-07
申请人： JANSSEN PHARMACEUTICA N.V. , BAUMANN, Christian, Andrew , GAUL, Michael David , TUMAN, Robert, W. , JOHNSON, Dana, L.
发明人： BAUMANN, Christian, Andrew , GAUL, Michael David , TUMAN, Robert, W. , JOHNSON, Dana, L.
IPC分类号： A61K31/517 , A61P35/00 , A61K31/4709 , A61K31/00
CPC分类号： A61K31/4709 , A61K31/00 , A61K31/496 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , A61K2300/00
摘要： The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from alkylquinoline and alkylquinazoline compounds of Formula (I'): where R 1 , R 2 , R 3 , Z, G, Q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.
摘要翻译：本发明涉及抑制FLT3酪氨酸激酶活性或在细胞或受试者中表达或降低FLT3激酶活性或表达的方法，其包括施用法呢基转移酶抑制剂和FLT3激酶抑制剂，所述法尼基转移酶抑制剂和FLT3激酶抑制剂选自烷基喹啉和烷基喹唑啉化合物（式 I'）：其中R 1，R 2，R 3，Z，G，Q和X如本文所定义。本发明包括预防和治疗方法，用于治疗患有（或易于）发展细胞增殖性病症或与FLT3相关的病症的受试者。

8. 发明申请

WO2008094896A1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS 审中-公开
标题翻译： N-取代的三茂胺3-氨基吡唑作为抗菌霉素聚合抑制剂
公开(公告)号：WO2008094896A1
公开(公告)日：2008-08-07
申请号：PCT/US2008/052288
申请日：2008-01-29
申请人： JANSSEN PHARMACEUTICA, N.V. , GALEMMO, Robert, A. , JOHNSON, Dana, L. , MAHAROOF, Umar S.M. , MEI, Jay, M. , TUMAN, Robert, W.
发明人： GALEMMO, Robert, A. , JOHNSON, Dana, L. , MAHAROOF, Umar S.M. , MEI, Jay, M. , TUMAN, Robert, W.
IPC分类号： C07D231/54 , C07D401/12 , A61K31/416 , A61P35/00
CPC分类号： C07D231/54 , C07D401/12
摘要： The invention is directed to compounds having the following structures: (formula I), N-(3-ethoxyphenyl)-1,4-dihydro-6-ethoxy-7-(3-hydroxypropoxy)-1-methylindeno[1,2- c]pyrazole-3-amine; (formula II), 3-[3-(3-Bromo-phenylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol; or (formula III), 3-[3-(2-Chloro-pyridin-4-ylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol, and N oxides, pharmaceutically acceptable salts, solvates, tautomers and stereochemical isomers thereof and the uses of such compounds as inhibitors of tubulin polymerization and for the treatment of solid tumors. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
摘要翻译：本发明涉及具有以下结构的化合物：（式I），N-（3-乙氧基苯基）-1,4-二氢-6-乙氧基-7-（3-羟基丙氧基）-1-甲基茚并〔1,2- c]吡唑-3-胺; （式II），3- [3-（3-溴 - 苯基氨基）-6-乙氧基-1-甲基-1,4-二氢 - 茚并[1,2-c]吡唑-7-基氧基] - 丙-1-酮醇; 或（式III），3- [3-（2-氯 - 吡啶-4-基氨基）-6-乙氧基-1-甲基-1,4-二氢 - 茚并[1,2-c]吡唑-7-基氧基 ] - 丙-1-醇和N氧化物，其药学上可接受的盐，溶剂合物，互变异构体和立体化学异构体以及这些化合物作为微管蛋白聚合抑制剂和用于治疗实体瘤的用途。本发明进一步涉及包含本发明化合物的药物组合物和治疗诸如癌症和其它细胞增殖性疾病的病症的方法。

9. 发明申请

WO2007075567A1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS 审中-公开
标题翻译：作为酪氨酸激酶调节剂的三唑并吡啶
公开(公告)号：WO2007075567A1
公开(公告)日：2007-07-05
申请号：PCT/US2006/048241
申请日：2006-12-18
申请人： JANSSEN PHARMACEUTICA, N.V. , LU, Tianbao , ALEXANDER, Richard , CONNORS, Richard, W. , CUMMINGS, Maxwell, D. , GALEMMO, Robert, A. , HUFNAGEL, Heather, Rae , JOHNSON, Dana, L. , KHALIL, Ehab , LEONARD, Kristi, A. , MARKOTAN, Thomas, P. , MARONEY, Anna, C. , SECHLER, Jan, L. , TRAVINS, Jeremy, M. , TUMAN, Robert, W.
发明人： LU, Tianbao , ALEXANDER, Richard , CONNORS, Richard, W. , CUMMINGS, Maxwell, D. , GALEMMO, Robert, A. , HUFNAGEL, Heather, Rae , JOHNSON, Dana, L. , KHALIL, Ehab , LEONARD, Kristi, A. , MARKOTAN, Thomas, P. , MARONEY, Anna, C. , SECHLER, Jan, L. , TRAVINS, Jeremy, M. , TUMAN, Robert, W.
IPC分类号： C07D487/04 , C07D519/00 , A61K31/5025
CPC分类号： C07D487/04 , C07D519/00
摘要： The invention is directed to triazolopyridazine compounds of Formula (I): where R 1 , R 5 , R 6 , R 7 , R 8 , and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
摘要翻译：本发明涉及式（I）的三唑并哒嗪化合物：其中R 1，R 5，R 6，R 7， A，R 8和A如本文所定义，使用这些化合物作为蛋白质酪氨酸激酶调节剂，特别是c-Met的抑制剂，以及使用这些化合物来降低或抑制激酶 c-Met在细胞或受试者中的活性和调节细胞或受试者中的c-Met表达，以及这些化合物在受试者中预防或治疗细胞增殖性疾病和/或与c-Met相关的疾病的用途。本发明进一步涉及包含本发明化合物的药物组合物和治疗诸如癌症和其它细胞增殖性疾病的病症的方法。

10. 发明申请

WO2007048088A3 METHOD OF INHIBITING FLT3 KINASE 审中-公开
标题翻译：抑制FLT3激酶的方法
公开(公告)号：WO2007048088A3
公开(公告)日：2007-06-07
申请号：PCT/US2006060028
申请日：2006-10-17
申请人： JANSSEN PHARMACEUTICA NV , BALLENTINE SHELLEY K , BAUMANN CHRISTIAN ANDREW , CHEN JINGSHENG , ILLIG CARL R , MEEGALLA SANETH , RUDOLPH M JONATHAN , TUMAN ROBERT W , WALL MARK J , WILSON KENNETH , JOHNSON DANA L
发明人： BALLENTINE SHELLEY K , BAUMANN CHRISTIAN ANDREW , CHEN JINGSHENG , ILLIG CARL R , MEEGALLA SANETH , RUDOLPH M JONATHAN , TUMAN ROBERT W , WALL MARK J , WILSON KENNETH , JOHNSON DANA L
IPC分类号： A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/5355 , A61P35/00
CPC分类号： A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/5355 , Y10S514/908
摘要： A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
摘要翻译：在细胞或受试者中减少或抑制FLT3的激酶活性的方法，以及这些化合物用于预防或治疗受试者细胞增殖性病症和/或与FLT3相关的病症的用途，其中使用本发明的化合物（I ）或其溶剂化物，水合物，互变异构体或药学上可接受的盐。本发明还涉及治疗诸如癌症和其他细胞增殖性病症的病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式